Ezh2、Runx3和caspase-3在子宫内膜样腺癌中的表达及相关性

目的 探讨Ezh2、Runx3和caspase-3在正常子宫内膜、子宫内膜增殖症和子宫内膜样腺癌组织中的表达及相关性.方法 采用组织芯片技术和免疫组织化学SP法检测30例正常子宫内膜组织、30例单纯性增生内膜、30例复杂伴不典型增生内膜、72例子宫内膜样腺癌组织中Ezh2、Runx3和caspase-3蛋白的表达.结果 Ezh2、Runx3和caspase-3蛋白在子宫内膜样腺癌组织中的阳性表达率分别为83.3%(60/72)、26.4%(19/72)、33.3%(24/72);Ezh2在腺癌组织中的阳性率明显高于正常和各型增生内膜(16.7%、33.3%、63.3%;P<0.05),Runx3在腺癌组织中的阳性率明显低于正常和单纯性增生内膜(80.0%、56.7%;P<0.01),caspase-3在腺癌组织中的阳性率明显低于正常和各型增生内膜(86.7%、73.3%、63.3%;P<0.01),差异均有统计学意义.Ezh2和Runx3的阳性表达与组织分级、临床分期和肌层浸润深度均有关(均P<0.05),与淋巴结转移均无关(P>0.05);caspase-3的阳性表达与组织分级有关(P<0.05),而与临床分期、浸润深度及淋巴结转移均无关(P>0.05).Ezh2与Runx3的蛋白表达呈负相关(rs=-0.262,P<0.05).结论 Ezh2、Runx3和caspase-3可能在子宫内膜样腺癌的发生发展过程中发挥重要作用,联合检测其表达可为子宫内膜样腺癌的预后监测及新基因靶点的探寻提供依据.

Abstract：

Objective To investigate the role of the expression of Ezh2, Runx3 and caspase-3 proteins and their correlation in the pathogenesis of endometrial carcinoma. Methods Expression of Ezh2, Runx3 and caspase-3 proteins was examined by tissue microarray technique and immunohistochemistry (SP method) in 72 cases of endometrial adenocarcinomas, 60 endometrial hyperplasia and 30 normal endometrial tissues. Results The positive expression rates of Ezh2, Runx3 and caspase-3 proteins in endometrial adenocarcinomas were 83.3%(60/72), 26.4%(19/72) and 33.3%(24/72), respectively. The positive rate of Ezh2 protein in endometrial carcinomas was higher than that in normal endometrium and endometrial hyperplasia(16.7%, 33.3%, 63.3%;P<0.05). However, the positive rate of Runx3 in endometrial carcinomas was lower than that in normal endometrium and endometrial hyperplasia(80.0%,56.7%; P<0.01). The positive rate of caspase-3 protein in endometrial carcinomas was lower than that in normal endometrium and endometrial hyperplasia(86.7%, 73.3%, 63.3%;P<0.01). Positive expression of Ezh2 and Runx3 was related to the histological grade, FIGO stage, and depth of invasion of endometrial adenocarcinomas(P<0.05), but it was not related to the lymph node metastasis (P>0.05). Positive expression of caspase-3 protein was related to the histological grade(P<0.05), but it was not related to the FIGO stage, depth of invasion and the lymph node metastasis of endometrial adenocarcinomas (P>0.05). The expression of Ezh2 protein was negatively correlated to that of Runx3 (rs=-0.262, P<0.05). Conclusions Abnormal expression of Ezh2, Runx3 and caspase-3 proteins is associated with the development and progression of endometrioid adenocarcinoma. Combined analysis of Ezh2, Runx3 and caspase-3 may offer prognostic information for patients with endometrial cancer.

Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma

Objective To investigate the role of the expression of Ezh2, Runx3 and caspase-3 proteins and their correlation in the pathogenesis of endometrial carcinoma. Methods Expression of Ezh2, Runx3 and caspase-3 proteins was examined by tissue microarray technique and immunohistochemistry (SP method) in 72 cases of endometrial adenocarcinomas, 60 endometrial hyperplasia and 30 normal endometrial tissues. Results The positive expression rates of Ezh2, Runx3 and caspase-3 proteins in endometrial adenocarcinomas were 83.3%(60/72), 26.4%(19/72) and 33.3%(24/72), respectively. The positive rate of Ezh2 protein in endometrial carcinomas was higher than that in normal endometrium and endometrial hyperplasia(16.7%, 33.3%, 63.3%;P<0.05). However, the positive rate of Runx3 in endometrial carcinomas was lower than that in normal endometrium and endometrial hyperplasia(80.0%,56.7%; P<0.01). The positive rate of caspase-3 protein in endometrial carcinomas was lower than that in normal endometrium and endometrial hyperplasia(86.7%, 73.3%, 63.3%;P<0.01). Positive expression of Ezh2 and Runx3 was related to the histological grade, FIGO stage, and depth of invasion of endometrial adenocarcinomas(P<0.05), but it was not related to the lymph node metastasis (P>0.05). Positive expression of caspase-3 protein was related to the histological grade(P<0.05), but it was not related to the FIGO stage, depth of invasion and the lymph node metastasis of endometrial adenocarcinomas (P>0.05). The expression of Ezh2 protein was negatively correlated to that of Runx3 (rs=-0.262, P<0.05). Conclusions Abnormal expression of Ezh2, Runx3 and caspase-3 proteins is associated with the development and progression of endometrioid adenocarcinoma. Combined analysis of Ezh2, Runx3 and caspase-3 may offer prognostic information for patients with endometrial cancer.